Drug Profile
Research programme: spinal cord injury and cancer therapies - Renovis/Genentech
Alternative Names: Nerve regeneration/anti-angiogenesis programme; Spinal cord injury therapies research programme - RenovisLatest Information Update: 29 Jun 2009
Price :
$50
*
At a glance
- Originator Renovis
- Developer Genentech; Renovis
- Class Proteins; Small molecules
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Brain injuries; Cancer; Spinal cord injuries
Most Recent Events
- 03 May 2008 Renovis has been acquired by Evotec AG
- 31 Oct 2005 Renovis and Genentech are in discussions about the future of this programme
- 15 Dec 2003 Preclinical trials in Cancer in USA (unspecified route)